InFo Hämatologie + Onkologie

, Volume 22, Issue 9, pp 18–23 | Cite as

Schwerpunkt nichtkleinzelliges Lungenkarzinom

Strahlentherapie des nichtkleinzelligen Lungenkarzinoms

  • Florian WürschmidtEmail author

Die Strahlentherapie ist ein wichtiger Baustein in der lokalen Behandung des NSCLC. Dabei wurden in jüngerer Zeit erhebliche Verbesserungen im Hinblick auf Bestrahlungsplanung, Strahlanwendung und bildgeführte Überwachung erzielt. Diese helfen, die Effektivität der Therapie zu erhöhen und Toxizitäten zu reduzieren. Lesen Sie nachfolgend das Wichtigste zu Grundlagen und Anwendung der Radiotherapie, Schwerpunkt ist das NSCLC.


  1. 1.
    Goldstraw P et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016;11(1):39–51CrossRefGoogle Scholar
  2. 2.
    Rowell NP, Williams CJ. Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable). Cochrane Database Syst Rev. 2001;(2):CD002935Google Scholar
  3. 3.
    Chun SG et al. Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial. J Clin Oncol. 2017;35(1):56–62CrossRefPubMedGoogle Scholar
  4. 4.
    Atagi S et al. Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). Lancet Oncol. 2012;13(7):671–8CrossRefPubMedGoogle Scholar
  5. 5.
    Eberhardt WE et al. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE). J Clin Oncol. 2015;33(35):4194–201CrossRefPubMedGoogle Scholar
  6. 6.
    Bradley JD et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16(2):187–99CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Antonia SJ et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017;377(20):1919–29CrossRefGoogle Scholar
  8. 8.
    Shaverdian N et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 2017;18(7):895–903CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Weichselbaum RR et al. Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol. 2017;14(6):365–79CrossRefPubMedGoogle Scholar
  10. 10.
    Rieber J et al. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group „stereotactic radiotherapy“. Lung Cancer. 2016;97:51–8CrossRefPubMedGoogle Scholar
  11. 11.
    Guckenberger M et al. Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation. Int J Radiat Oncol Biol Phys. 2009;74(1):47–54CrossRefPubMedGoogle Scholar
  12. 12.
    Tekatli H et al. Outcomes of Hypofractionated High-Dose Radiotherapy in Poor-Risk Patients with „Ultracentral“ Non-Small Cell Lung Cancer. J Thorac Oncol. 2016;11(7):1081–9CrossRefPubMedGoogle Scholar
  13. 13.
    Chang JY et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015;16(6):630–7CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Ball D et al. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. Lancet Oncol. 2019;20(4):494–503CrossRefPubMedGoogle Scholar
  15. 15.
    Gomez DR et al. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol. 2019;37(18):1558–65CrossRefPubMedGoogle Scholar
  16. 16.
    Buderi SI et al. Does induction chemoradiotherapy increase survival in patients with Pancoast tumour? Interact Cardiovasc Thorac Surg. 2016;23(5):821–825CrossRefPubMedGoogle Scholar
  17. 17.
    Douillard JY et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7(9):719–27CrossRefGoogle Scholar
  18. 18.
    Douillard JY et al. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial. Int J Radiat Oncol Biol Phys. 2008;72(3):695–701CrossRefPubMedGoogle Scholar
  19. 19.
    Faivre-Finn C et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017;18(8):1116–25CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Slotman BJ et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet. 2015;385(9962):36–42CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Radiologische Allianz GbRHamburgDeutschland

Personalised recommendations